Skip to main content
Equibles
AMGN logo

AMGN · Amgen Inc · Earnings Call Transcripts & Audio

Track AMGN — free

Use AMGN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AMGN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$392.59 +1.32 (+0.34%)
S&P 500 member Nasdaq-100 member Russell 1000 member Dow 30 member Rebalance outlook locked
Market Cap
$219.51B
Shares
540.63M

Amgen Inc Earnings Call Transcripts

Quarterly earnings calls for Amgen Inc (AMGN), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲1% $6.59B $1.32B '22 Q2 22-08-04 ▼0.8% $6.65B $2.14B '22 Q3 22-11-03 ▼0.1% $6.84B $1.62B '22 Q4 23-01-31 ▼2.1% $6.11B $2.84B '23 Q1 23-04-27 ▲5.9% $6.99B $1.38B '23 Q2 23-08-03 ▲3.8% $6.90B $1.73B '23 Q3 23-10-31 ▲19.8% $8.20B $767.00M '23 Q4 24-02-06 ▲22% $7.45B −$113.00M '24 Q1 24-05-02 ▲20.1% $8.39B $746.00M '24 Q2 24-08-06 ▲23.2% $8.50B $2.83B '24 Q3 24-10-30 ▲10.9% $9.09B $627.00M '24 Q4 25-02-04 ▲9.4% $8.15B $1.73B '25 Q1 25-05-01 ▲9.4% $9.18B $1.43B '25 Q2 25-08-05 ▲12.4% $9.56B $3.22B '25 Q3 25-11-04 ▲8.6% $9.87B $1.33B '25 Q4 26-02-03 LATEST ▲9.5% $10.05B $2.38B '26 Q2 26-08-04
Conference
Investor event
2026-09-06
Amgen Inc (AMGN) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-04
Amgen Inc (AMGN) Q2 2026 Earnings Call Transcript
Confident tone Repatha (PCSK9 / cardiovascular) Obesity / MariTide pipeline Six key growth drivers / portfolio breadth
Revenue
$10.05B
▲ 9.5% YoY
Diluted EPS
$4.37
▲ 64.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-03
Amgen Inc (AMGN) Q4 2025 Earnings Call Transcript
Positive tone Meritide obesity pipeline Growth drivers (Repatha, Evenity, TestSpire) Tavneos / ChemoCentryx FDA request for withdrawal
Revenue
$9.87B*
▲ 8.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Amgen Inc (AMGN) Q3 2025 Earnings Call Transcript
Confident tone Cardiovascular franchise (Repatha, Olpasiran) Rare diseases and UPLIZNA expansion Volume growth and broad portfolio momentum
Revenue
$9.56B
▲ 12.4% YoY
Diluted EPS
$5.93
▲ 13.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Amgen Inc (AMGN) Q2 2025 Earnings Call Transcript
Confident tone MariTide obesity program Oncology and BiTE platform General medicine portfolio (Repatha, EVENITY, Prolia)
Revenue
$9.18B
▲ 9.4% YoY
Diluted EPS
$2.65
▲ 92% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Amgen Inc (AMGN) Q1 2025 Earnings Call Transcript
Confident tone Obesity / MariTide Rare disease (TEPEZZA, KRYSTEXXA, UPLIZNA, TAVNEOS) Cardiovascular / Repatha
Revenue
$8.15B
▲ 9.4% YoY
Diluted EPS
$3.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-04
Amgen Inc (AMGN) Q4 2024 Earnings Call Transcript
Confident tone Pipeline catalysts (MariTide, rocatinlimab, oncology) Repatha expansion Rare disease portfolio / TEPEZZA international
Revenue
$9.09B*
▲ 10.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-30
Amgen Inc (AMGN) Q3 2024 Earnings Call Transcript
Confident tone Rare disease franchise (Horizon) MariTide (obesity/obesity-related pipeline) General medicine growth (Repatha, EVENITY, Prolia)
Revenue
$8.50B
▲ 23.2% YoY
Diluted EPS
$5.22
▲ 62.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Amgen Inc (AMGN) Q2 2024 Earnings Call Transcript
Confident tone MariTide / obesity pipeline Oncology launches and label expansions Pipeline breadth and 2024 milestones
Revenue
$8.39B
▲ 20.1% YoY
Diluted EPS
$1.38
▼ 46.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Amgen Inc (AMGN) Q1 2024 Earnings Call Transcript
Confident tone TEPEZZA safety/monitoring and subcutaneous development MariTide (obesity/obesity-related conditions/diabetes) Rare disease / Horizon integration
Revenue
$7.45B
▲ 22% YoY
Diluted EPS
$-0.21
▼ 104% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-06
Amgen Inc (AMGN) Q4 2023 Earnings Call Transcript
Positive tone Horizon Acquisition / Rare Disease Pillar MariTide / Obesity Pipeline Volume Growth & Geographic Expansion
Revenue
$8.20B*
▲ 19.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-10-31
Amgen Inc (AMGN) Q3 2023 Earnings Call Transcript
Revenue
$6.90B
▲ 3.8% YoY
Diluted EPS
$3.22
▼ 19.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Amgen Inc (AMGN) Q2 2023 Earnings Call Transcript
Revenue
$6.99B
▲ 5.9% YoY
Diluted EPS
$2.57
▲ 4.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-04-27
Amgen Inc (AMGN) Q1 2023 Earnings Call Transcript
Revenue
$6.11B
▼ 2.1% YoY
Diluted EPS
$5.28
▲ 97% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-31
Amgen Inc (AMGN) Q4 2022 Earnings Call Transcript
Revenue
$6.84B*
▼ 0.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Amgen Inc (AMGN) Q3 2022 Earnings Call Transcript
Revenue
$6.65B
▼ 0.8% YoY
Diluted EPS
$3.98
▲ 20.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Amgen Inc (AMGN) Q2 2022 Earnings Call Transcript
Revenue
$6.59B
▲ 1% YoY
Diluted EPS
$2.45
▲ 202.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-04-27
Amgen Inc (AMGN) Q1 2022 Earnings Call Transcript
Revenue
$6.24B
▲ 5.7% YoY
Diluted EPS
$2.68
▼ 5.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-07
Amgen Inc (AMGN) Q4 2021 Earnings Call Transcript
Revenue
$6.85B*
▲ 3.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Amgen Inc (AMGN) Q3 2021 Earnings Call Transcript
Revenue
$6.71B
▲ 4.4% YoY
Diluted EPS
$3.31
▼ 3.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Amgen Inc (AMGN) Q2 2021 Earnings Call Transcript
Revenue
$6.53B
▲ 5.2% YoY
Diluted EPS
$0.81
▼ 73.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-04-27
Amgen Inc (AMGN) Q1 2021 Earnings Call Transcript
Revenue
$5.90B
▼ 4.2% YoY
Diluted EPS
$2.83
▼ 7.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-02
Amgen Inc (AMGN) Q4 2020 Earnings Call Transcript
Revenue
$6.63B*
▲ 7.1% YoY
Diluted EPS
$2.76
▼ 3.2% YoY
Gross margin
71.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-10-28
Amgen Inc (AMGN) Q3 2020 Earnings Call Transcript
Revenue
$6.42B
▲ 12% YoY
Diluted EPS
$3.43
▲ 4.9% YoY
Gross margin
70.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-07-28
Amgen Inc (AMGN) Q2 2020 Earnings Call Transcript
Revenue
$6.21B
▲ 5.7% YoY
Diluted EPS
$3.05
▼ 14.6% YoY
Gross margin
71.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-04-30
Amgen Inc (AMGN) Q1 2020 Earnings Call Transcript
Revenue
$6.16B
▲ 10.9% YoY
Diluted EPS
$3.07
▼ 3.5% YoY
Gross margin
71.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–26 of 26 earnings calls
Key facts CIK 318154 CUSIP 031162100 13F (30d) 1003 filings 954 filers Visit website Investor relations